Federated Hermes Inc. Lowers Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Federated Hermes Inc. trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 84.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,003 shares of the medical research company’s stock after selling 10,491 shares during the period. Federated Hermes Inc.’s holdings in Edwards Lifesciences were worth $153,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of EW. Commonwealth Equity Services LLC increased its holdings in Edwards Lifesciences by 7.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 163,984 shares of the medical research company’s stock valued at $11,361,000 after acquiring an additional 11,117 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Edwards Lifesciences by 2.6% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,392 shares of the medical research company’s stock worth $2,729,000 after purchasing an additional 1,011 shares during the last quarter. Verdence Capital Advisors LLC lifted its stake in Edwards Lifesciences by 16.3% in the 3rd quarter. Verdence Capital Advisors LLC now owns 9,321 shares of the medical research company’s stock valued at $646,000 after buying an additional 1,303 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Edwards Lifesciences by 77.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,071 shares of the medical research company’s stock valued at $28,410,000 after buying an additional 179,583 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in Edwards Lifesciences by 13.7% during the 3rd quarter. Mackenzie Financial Corp now owns 159,116 shares of the medical research company’s stock valued at $11,074,000 after buying an additional 19,208 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on EW shares. Oppenheimer upped their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Mizuho upped their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Finally, Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $92.71.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the sale, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders have sold 237,749 shares of company stock valued at $20,920,934 over the last three months. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $85.25 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a market cap of $51.37 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The stock’s 50-day moving average is $90.08 and its 200-day moving average is $79.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.